The leading Cutaneous Squamous Cell Carcinoma Companies such as Incyte Corporation, Shanghai Henlius Biotech, Novartis, ...

So we delivered another strong year with 2024 total revenues growing 15% versus 2023 to reach $4.2 billion, continuing the steady growth ... and our CDK2 inhibitor in ovarian cancer.

Here, the authors developed a cell-based screening assay for the identification of small molecule inhibitors of nonsense-mediated decay (NMD), and used it to validate KVS0001, a new small molecule ...

A study from the FIRST registry finds that rheumatoid arthritis patients with an inadequate response to JAK inhibitors may ...

Discover how next-generation kinase inhibitors are transforming clinical therapy byovercoming resistance and enhancing ...

Upadacitinib will face two main JAK inhibitor competitors – Eli Lilly’s Olumiant and Pfizer’s Xeljanz. Despite excitement surrounding the class, though, these treatments all face a complex ...

I-Mab (IMAB) stock gains as an early-stage trial for its gastric cancer therapy givastomig advances in a faster than expected ...

Research by UMass Chan Medical School scientists Sharon Cantor, PhD, and Jenna M. Whalen, PhD, poses a new explanation for how cancer-fighting drugs attack and destroy BRCA1 and BRCA2 tumor cells.